Bangalore-based biotech major Biocon launched 'BIOMAb-EGFR', a therapeutic monoclonal antibody-based drug for treating head and neck cancer.
The drug was launched in Bangalore on Sunday by actor Shah Rukh Khan. BIOMAb-EGFR will be available as a unit carton of four 10 ml vials.
Biocon's latest drug is engineered to specifically target and block the epidermal growth factor receptor responsible for the proliferation of cancer cells.
This drug application is to be combined with radiation therapy/chemotherapy in patients with a positive expression of EGFR in squamous cell carcinoma of head and neck.
During clinical trials, BIOMAb-EGFR showed an extensive proliferation inhibiting activity in non-small cell lung cancer, breast cancer, colorectal cancer, pancreatic cancer and glioblastoma (brain tumour).
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
